Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.
Winqvist M, Asklid A, Andersson PO, Karlsson K, Karlsson C, Lauri B, Lundin J, Mattsson M, Norin S, Sandstedt A, Hansson L, Österborg A. Winqvist M, et al. Among authors: asklid a. Haematologica. 2016 Dec;101(12):1573-1580. doi: 10.3324/haematol.2016.144576. Epub 2016 May 19. Haematologica. 2016. PMID: 27198718 Free PMC article.
First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013.
Sylvan SE, Asklid A, Johansson H, Klintman J, Bjellvi J, Tolvgård S, Kimby E, Norin S, Andersson PO, Karlsson C, Karlsson K, Lauri B, Mattsson M, Sandstedt AB, Strandberg M, Österborg A, Hansson L. Sylvan SE, et al. Among authors: asklid a. Haematologica. 2019 Apr;104(4):797-804. doi: 10.3324/haematol.2018.200204. Epub 2018 Nov 22. Haematologica. 2019. PMID: 30467205 Free PMC article. Clinical Trial.
Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort.
Winqvist M, Andersson PO, Asklid A, Karlsson K, Karlsson C, Lauri B, Lundin J, Mattsson M, Norin S, Sandstedt A, Rosenquist R, Späth F, Hansson L, Österborg A; Swedish CLL Group. Winqvist M, et al. Among authors: asklid a. Haematologica. 2019 May;104(5):e208-e210. doi: 10.3324/haematol.2018.198820. Epub 2018 Dec 4. Haematologica. 2019. PMID: 30514799 Free PMC article. No abstract available.
Risk-adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real-world report on 141 consecutive Swedish patients.
Mattsson A, Sylvan SE, Asklid A, Wiggh J, Winqvist M, Lundin J, Mansouri L, Rosenquist R, Johansson H, Österborg A, Hansson L. Mattsson A, et al. Among authors: asklid a. Br J Haematol. 2020 Nov;191(3):426-432. doi: 10.1111/bjh.17032. Epub 2020 Aug 10. Br J Haematol. 2020. PMID: 32779190 Free PMC article.
Re-irradiation in Paediatric Tumours of the Central Nervous System: National Guidelines from the Swedish Workgroup of Paediatric Radiotherapy.
Embring A, Blomstrand M, Asklid A, Nilsson MP, Agrup M, Svärd AM, Fröjd C, Martinsson U, Fagerström Kristensen I, Engellau J. Embring A, et al. Among authors: asklid a. Clin Oncol (R Coll Radiol). 2023 Sep;35(9):571-575. doi: 10.1016/j.clon.2023.05.007. Epub 2023 May 19. Clin Oncol (R Coll Radiol). 2023. PMID: 37246041
Complications after proton radiotherapy in children, focusing on severe late complications. A complete Swedish cohort 2008-2019.
Martinsson U, Svärd AM, Witt Nyström P, Embring A, Asklid A, Agrup M, Haugen H, Fröjd C, Engellau J, Nilsson MP, Isacsson U, Kristensen I, Blomstrand M. Martinsson U, et al. Among authors: asklid a. Acta Oncol. 2023 Oct;62(10):1348-1356. doi: 10.1080/0284186X.2023.2260946. Epub 2023 Nov 7. Acta Oncol. 2023. PMID: 37768736 Free article.